학술논문
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Document Type
Article
Author
Source
In The Lancet HIV July 2018 5(7):e357-e365
Subject
Language
ISSN
2352-3018